Dr. Axel Mescheder Steps Down as Chief Medical Officer
APTA Therapeutics GmbH would like to extend its warmest thanks to Dr. Axel Mescheder for his outstanding leadership, dedication and foresight in advancing the clinical development of rovunaptabin for the treatment of post-acute viral syndrome. Although Dr. Mescheder is stepping down from his role as Chief Medical Officer, APTA hopes that he will remain closely involved in the further development of rovunaptabin.